Zimmer Biomet Signs Multi-Year Agreement with Surgical Planning Associates to Commercialize HipInsight

September 2, 2022

Trending News ☀️

The agreement between Zimmer Biomet($NYSE:ZBH) and Surgical Planning Associates will allow HipInsight to be commercialized, meaning that it can be used by surgeons to help with placement and alignment of hip implants. This system projects a hologram of the patient’s pelvic anatomy onto the pelvis during surgery, using Microsoft HoloLens 2 glasses. Some may worry that this will have a negative effect on Zimmer Biomet’s market and earnings in the long term. However, it is likely that this agreement will actually help to increase both. By providing a product that can improve the accuracy and efficiency of hip replacement surgery, Zimmer Biomet will be able to attract more customers. In addition, the company will earn a share of the revenue from each sale of HipInsight.

Price History

Under the terms of the agreement, SPA will receive an upfront payment as well as royalties on future sales of the product. This is a positive development for Zimmer Biomet, as HipInsight is a potentially valuable tool that can help surgeons plan hip surgeries more effectively. In addition, the agreement provides a source of revenue for SPA, which can help the company continue to develop new products.

VI Analysis

Zimmer Biomet is a medical device company that designs, manufactures and markets musculoskeletal health solutions. The company’s products and services help treat patients suffering from conditions such as osteoarthritis, spinal disorders and trauma. Based on the company’s fundamentals, Zimmer Biomet is a high risk investment in terms of financial and business aspects. The company’s financial stability is weak, with a high debt-to-equity ratio and negative free cash flow. Additionally, the company faces significant business risks, such as intense competition, regulatory scrutiny and litigation risks. Investors should carefully consider these risks before investing in Zimmer Biomet. Those who do choose to invest should monitor the company closely and be prepared to sell if the risks materialize.

For more details please visit Risk Rating.


This agreement builds on the existing relationship between the two companies, and will help Zimmer Biomet to expand its reach in the hip replacement market. HipInsight is a valuable tool that can help surgeons to plan and execute complex hip replacement surgeries with greater precision and accuracy. This, in turn, can lead to better patient outcomes and satisfaction. The agreement between Zimmer Biomet and SPA is a positive development for both companies. It will help Zimmer Biomet to grow its business and extend its reach in the hip replacement market, while also providing SPA with access to a valuable tool that can help it to improve patient outcomes.

Recent Posts

Leave a Comment